Salix Pharmaceuticals, the gastrointestinal drug specialist, has snapped up fellow specialty drugmaker Santarus in a $2.6 billion all-cash buyout.
EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.
Our readers who regularly check our website know that we kept up with the news online. But for everyone else, here's a roundup of the regulatory actions you may have missed.
On the last day of the year, the FDA gave a thumbs up to the second botanical prescription drug it has ever approved, a full 6 years after the first was sanctioned. The recipient of this rare distinction was Fulyzaq, a drug marketed by Salix Pharmaceuticals for the treatment of diarrhea in HIV/AIDS patients who are on anti-retroviral therapy.
Racking up yet another year-end approval, the FDA today OK'd Salix's crofelemer for use in treating HIV-related diarrhea. The drug, to be marketed as Fulyzaq, is derived from the red sap of the Croton lechleri plant, making this the second botanical drug ever approved by the FDA.
Breaking from a long string of trial failures, AstraZeneca offered up positive data from a pair of late-stage Phase III study of naloxegol, an experimental drug for opioid-induced constipation in-licensed from Nektar ($NKTR) in a $1.5 billion deal. The treatment hit its endpoint for both doses in one study while only the high dose cleared that bar in the second study.
Salix is snapping up Oceana Therapeutics for $300 million. Oceana has a pair of drugs on the market: Deflux, which is used to treat vesicoureteral reflux, a bladder problem known to trigger severe
Salix Pharmaceuticals didn't win the FDA's blessing to market Xifaxan as a remedy for irritable bowel syndrome, a potentially lucrative new use for the drug, which is now approved for traveler's
Salix Pharmaceuticals took a body blow from FDA, as the agency refused to broaden use of its bowel drug Xifaxan. Widely expected to win an indication for use in irritable bowel syndrome, Xifaxan is
Salix Pharmaceuticals has agreed to pay up to roughly $130 million for the licensing rights to a new imaging technology that can be used to spot precancerous lesions in the colon. Doctors currently